Other Events ·
Verastem reports 86% six-month overall survival in RAMP 205 trial of avutometinib plus defactinib for pancreatic cancer
VSTMVerastem, Inc.
Verastem, Inc. announced positive updated results from the RAMP 205 Phase 1b/2a trial evaluating avutometinib plus defactinib with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal carcinoma. The combination therapy demonstrated an 86% overall survival rate at 6 months, a 68% progression-free survival rate at 6 months, and a 52% confirmed objective response rate. Additionally, the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial evaluating VS-7375 for KRAS G12D-mutated mPDAC. Verastem, Inc. is a biopharmaceutical company focused on developing investigational oncology-related drugs.